Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
781-800 of 1,307 trials

Viral Infections After Stem Cell Transplant: Multispecific T-Cell Therapy

We are studying a new treatment using multispecific T-cells for patients with viral infections that resist chemotherapy after stem cell transplantation. The goal is to see if this therapy can improve symptoms and overall health.

Viral Infections After Stem Cell Transplant>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesHematologyInfectious DiseasesOncology

Migraine Prevention in Kids: Rimegepant Study

We are testing a new medication, rimegepant, to see if it helps reduce migraine days in children and adolescents aged 6 to under 18. The study compares its effects to a placebo to understand its potential benefits.

Migraine≤3 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurologyPediatrics

Anesthesia in Young Children: Low-Dose vs. Standard Sevoflurane

We are comparing the effects of low-dose sevoflurane combined with dexmedetomidine and remifentanil against standard sevoflurane anesthesia on cognitive development in children under 2 years old. The goal is to see which method supports better brain development as they grow.

General Anesthesia in Young Children>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOtolaryngologyPediatrics

Cardiac Surgery: Fibrinogen Concentrate Study

We are testing a new treatment to manage bleeding in patients undergoing complex cardiac surgery. The goal is to see if it reduces the need for blood transfusions compared to a placebo.

Functional Disturbances After Cardiac SurgeryBleeding in Cardiac Surgery Patients>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Hemolytic Uremic Syndrome: INM004 Treatment for Kids

We are studying a new treatment for children with Hemolytic Uremic Syndrome caused by E. coli to see if it helps improve kidney function and reduce complications. The trial will also evaluate the safety of this treatment.

Hemolytic Uremic Syndrome6-12 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementInfectious DiseasesNephrologyPediatrics

Soft Tissue Sarcomas: INT230-6 Treatment Study

We are investigating a new treatment for adults with advanced soft tissue sarcomas to see if it works better than standard care. The study will also look at side effects and quality of life for participants.

Myxoid LiposarcomaDedifferentiated LiposarcomaRound Cell Liposarcoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Organ Transplantation: Custodiol-N vs. Custodiol Solution

We are studying a new preservation solution for kidney, liver, and pancreas transplants to see if it works as well as the current standard. This research may help improve outcomes for transplant recipients.

Organ Transplant Candidates>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesEndocrinologyHepatologyInternal MedicineNephrologyOrthopedics and Traumatology

Bevacizumab vs. Corticosteroids for Cerebral Radiation Necrosis

We are studying whether bevacizumab is more effective than corticosteroids for treating symptoms of cerebral radiation necrosis in patients with high-grade glioma or brain metastases. The trial also looks at quality of life and other health impacts.

Brain MetastasesHigh-Grade Glioma>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyOncology

ANCA Vasculitis: Stopping Immunosuppressive Therapy

We are studying whether stopping immunosuppressive therapy helps patients with ANCA vasculitis and end-stage renal disease avoid serious health issues compared to continuing treatment.

End-stage Renal DiseaseANCA Vasculitis>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesNephrologyRheumatology

Cardiovascular Disease: Low Dose Rivaroxaban in Advanced CKD

We are studying whether a low dose of rivaroxaban can help reduce serious heart-related events in people with advanced chronic kidney disease or on dialysis. This trial compares the medication to a placebo to see if it offers any benefits.

Heart and Kidney Disease>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementCardiologyNephrology

Pancreatic Cancer: New Electroporation Treatments

We are studying the effects of three innovative treatments for pancreatic cancer to see if they improve quality of life and survival. This includes assessing pain levels and weight loss in patients.

Unresectable Pancreatic Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Depression: Pramipexole for Anhedonia Symptoms

We are studying whether pramipexole can help reduce anhedonia symptoms in people with depression. The trial will also look at its effects on overall mood, physical activity, and sleep quality.

AnhedoniaMajor DepressionConfirmation phase (III)Standard MedicinesPsychiatry

Plaque Psoriasis: TAK-279 Oral Medication

We are studying a new daily oral treatment for people with moderate-to-severe plaque psoriasis. The trial will help us understand its long-term safety and effectiveness.

Plaque Psoriasis>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementDermatology

Plaque Psoriasis: Zasocitinib vs. Deucravacitinib

We are studying whether a new oral medication, zasocitinib, is more effective than deucravacitinib for treating moderate-to-severe plaque psoriasis. The trial will also assess the safety and tolerability of both treatments.

Plaque Psoriasis6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementDermatology

CIDP Treatment: Rituximab Study

We are investigating whether adding Rituximab to IVIg treatment can help people with CIDP achieve long-term remission. This may reduce the need for regular infusions and associated healthcare costs.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Locally Recurrent Rectal Cancer: Induction Chemotherapy Study

We are comparing the effects of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone for patients with locally recurrent rectal cancer. This study aims to see which approach leads to better surgical outcomes and survival rates.

Recurrent Rectal CancerConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

Major Depressive Disorder: Ketamine and ECT Study

We are investigating whether combining ketamine with electroconvulsive therapy helps people with treatment-resistant depression. The study also examines its effects on brain chemicals and cognitive function.

Treatment Resistant DepressionMajor Depressive Disorder1-2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPsychiatry

Bladder Cancer: ONCOFID-P-B Treatment Study

We are studying a new treatment called ONCOFID-P-B for patients with Carcinoma in Situ of the bladder who have not responded to standard care. The goal is to see if this treatment can effectively reduce tumors and improve patient outcomes.

Bladder Cancer in Situ1-2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncology

HER2-Positive Gastric Cancer: Rilvegostomig Treatment Study

We are comparing a new treatment combining rilvegostomig with other medications to standard therapies for patients with HER2-positive gastric cancer. The goal is to see if this new approach improves survival and reduces disease progression.

HER2-positive Gastric Cancer>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Gene Therapy for Hearing Loss: AAVAnc80-hOTOF

We are studying a new gene therapy for people with hearing loss due to Otoferlin gene mutations. The trial aims to assess the long-term safety and effectiveness of this treatment.

Otoferlin Gene-Mediated Hearing Loss>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesInternal MedicineNeurologyOtolaryngology